^
Association details:
Evidence:
Evidence Level:
Sensitive: B - Late Trials
Title:

JICC01 - Joint IASLC-CAALC-CSCO Session: The Truth and Myth of Oral Anti-VEGFR Inhibitors for Advance NSCLC

Published date:
01/12/2021
Excerpt:
Lenvatinib resulted in a response rate of 16% and a median progression-free survival of 7.3 months among 25 patients with RET fusion-positive lung cancer.
Trial ID: